Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CRNX

CRNX - Crinetics Pharmaceuticals Inc Stock Price, Fair Value and News

46.84USD-0.94 (-1.97%)Market Closed

Market Summary

CRNX
USD46.84-0.94
Market Closed
-1.97%

CRNX Alerts

  • 2 major insider sales recently.

CRNX Stock Price

View Fullscreen

CRNX RSI Chart

CRNX Valuation

Market Cap

3.7B

Price/Earnings (Trailing)

-15.69

Price/Sales (Trailing)

1.9K

Price/Free Cashflow

-20.03

CRNX Price/Sales (Trailing)

CRNX Profitability

Return on Equity

-26.91%

Return on Assets

-24.07%

Free Cashflow Yield

-4.99%

CRNX Fundamentals

CRNX Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

CRNX Earnings

Earnings (TTM)

-235.5M

Earnings Growth (Yr)

-45.52%

Earnings Growth (Qtr)

-11.37%

Breaking Down CRNX Revenue

Last 7 days

2.2%

Last 30 days

-5.1%

Last 90 days

20.3%

Trailing 12 Months

129.7%

How does CRNX drawdown profile look like?

CRNX Financial Health

Current Ratio

17.72

CRNX Investor Care

Shares Dilution (1Y)

45.97%

Diluted EPS (TTM)

-3.77

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.0M000
20234.3M4.8M4.7M4.0M
20222.0M2.9M3.8M4.7M
20210001.1M
2020897.0K897.0K392.0K735.0K
20192.4M1.7M1.7M1.2M
20182.4M2.3M2.2M2.4M
2017953.0K1.3M1.7M2.0M
2016000589.0K

Tracking the Latest Insider Buys and Sells of Crinetics Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
betz stephen f.
sold
-131,580
43.86
-3,000
chief scientific officer
Jun 07, 2024
fust matthew k
acquired
-
-
3,400
-
Jun 07, 2024
wierenga wendall
acquired
-
-
3,400
-
Jun 07, 2024
okey stephanie
acquired
-
-
3,400
-
Jun 07, 2024
vivaldi coelho rogerio
acquired
-
-
3,400
-
Jun 07, 2024
bedrosian camille l
acquired
-
-
3,400
-
Jun 07, 2024
nichols weston
acquired
-
-
3,400
-
Jun 07, 2024
deardorf caren
acquired
-
-
3,400
-
May 28, 2024
betz stephen f.
sold
-142,470
47.49
-3,000
chief scientific officer
May 10, 2024
betz stephen f.
sold
-296,580
49.43
-6,000
chief scientific officer

1–10 of 50

Which funds bought or sold CRNX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-71.43
-2,744
1,490
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
96,000
498,000
-%
May 29, 2024
Opaleye Management Inc.
reduced
-31.71
-1,110,750
9,830,100
2.14%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-11.73
233,000
1,678,000
0.01%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
reduced
-95.93
-4,138,870
234,050
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
73.09
350,569
625,569
0.08%
May 17, 2024
Ikarian Capital, LLC
reduced
-5.38
5,926,420
30,134,000
3.30%
May 17, 2024
Artal Group S.A.
new
-
65,088,200
65,088,200
1.66%
May 16, 2024
AWM Investment Company, Inc.
added
10.00
795,550
2,574,550
0.34%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
11.1
950,459
3,009,510
-%

1–10 of 42

Are Funds Buying or Selling CRNX?

Are funds buying CRNX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRNX
No. of Funds

Unveiling Crinetics Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
ecor1 capital, llc
5.3%
4,155,375
SC 13G
Mar 01, 2024
perceptive advisors llc
1.9%
1,488,703
SC 13D/A
Feb 14, 2024
braidwell lp
0%
0
SC 13G/A
Feb 14, 2024
driehaus capital management llc
7.54%
5,039,477
SC 13G/A
Feb 14, 2024
biotechnology value fund l p
-
0
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
5.1%
3,416,900
SC 13G/A
Feb 14, 2024
orbimed advisors llc
2.5%
1,667,360
SC 13G/A
Feb 13, 2024
vanguard group inc
5.24%
3,502,452
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G
Feb 08, 2024
wellington management group llp
4.86%
3,245,105
SC 13G/A

Recent SEC filings of Crinetics Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 10, 2024
144
Notice of Insider Sale Intent
Jun 10, 2024
8-K
Current Report

Peers (Alternatives to Crinetics Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Crinetics Pharmaceuticals Inc News

Latest updates
MarketBeat10 hours ago

Crinetics Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-640,000-346,000988,0002,679,000709,000458,000439,0003,131,0002,087,3331,043,667--71,000321,000505,000-367,000781,000548,000657,000
Operating Expenses18.4%74,169,00062,658,00059,323,00053,983,00050,657,00048,265,00043,912,00043,484,00036,958,00031,966,00021,791,00018,451,00016,929,00017,853,00015,535,00015,734,00013,345,00010,411,00010,212,0008,618,0006,340,000
  S&GA Expenses22.0%20,828,00017,078,00015,484,00013,343,00012,189,00011,274,00011,925,00010,489,0008,706,0007,362,0004,961,0004,752,0004,322,0003,991,0003,392,0003,911,0003,060,0003,156,0002,561,0001,732,0001,118,000
  R&D Expenses17.0%53,341,00045,580,00043,839,00040,640,00038,468,00036,991,00031,987,00032,995,00028,252,00024,604,00016,830,00013,699,00012,607,00013,862,00012,143,00011,823,00010,285,0007,255,0007,651,0006,886,0005,222,000
EBITDA Margin---------14.95-8.52-99.00-1,026-126-55.16-55.18-41.51-15.87-15.52-11.26---
EBT Margin---------15.08-8.59-99.85-1,039-128-56.21-56.21-42.26-16.40-15.99-11.52---
Net Income-11.4%-66,930,000-60,097,000-57,458,000-50,979,000-45,995,000-44,991,000-41,925,000-42,375,000-34,627,000-30,794,000-21,641,000-18,320,000-16,491,000-17,360,000-14,549,000-14,430,000-12,427,000-9,016,000-8,495,000-7,588,000-5,568,000
Net Income Margin-123.1%-119-53.46-42.23-38.04-40.91-34.60-39.17-46.65-59.90-99.85-----------
Free Cashflow-37.4%-54,188,000-39,450,000-44,839,000-45,972,000-40,734,000-35,481,000-39,161,000-28,589,000-13,630,000-22,917,000-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets54.0%978635642293314352385422333351209217164183200217124130143155167
  Current Assets59.8%917574576285305345378416328345204211158177194211117123135148159
    Cash Equivalents621.2%39655.0014340.0041.0034.0031.0062.0014620116217910694.0011816151.0041.0067.0060.0063.00
  Net PPE9.0%12.0011.0010.003.003.004.004.003.003.003.003.003.003.003.003.004.004.004.004.004.004.00
Liabilities7.2%10396.0094.0039.0034.0036.0034.0036.0030.0019.0016.0015.0014.0015.0013.0014.0015.0013.0013.0013.0014.00
  Current Liabilities17.8%52.0044.0040.0033.0026.0028.0025.0026.0020.0016.0012.0012.0010.0010.009.0010.0011.008.008.008.009.00
Shareholder's Equity62.3%875539548254280316351386303332194201149169187203108117130142152
  Retained Earnings-10.2%-720-653-593-536-485-439-394-352-309-275-244-216-190-167-146-127-111-93.80-79.25-64.82-52.40
Shares Outstanding15.2%79.0068.0067.0055.0054.0054.0054.0050.0048.0038.0036.0035.00---------
Float----1,000---1,000---683---506---423-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-37.2%-52,856-38,515-41,339-45,735-40,718-35,207-38,479-27,976-13,543-22,899-25,673-19,949-20,067-15,938-18,004-15,855-12,230-13,447-13,607-12,568-6,759
  Share Based Compensation15.8%13,45411,61711,04910,1758,0967,9487,4347,1315,7555,1584,5554,2333,4062,9712,7812,5282,1471,8311,8541,5811,028
Cashflow From Investing100.4%309-87,308-193,29631,43648,75536,8536,822-174,271-43,384-101,798-7,02519,83832,502-8,892-24,83217,60216,339-12,82320,4489,44324,599
Cashflow From Financing937.8%393,57437,925337,87712,6584841151,076118,9921,780163,85615,46373,30357.0097.00-158108,1506,48217.0022.008.0020.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CRNX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenues$ 640$ 2,679
Operating expenses:  
Research and development53,34138,468
General and administrative20,82812,189
Total operating expenses74,16950,657
Loss from operations(73,529)(47,978)
Other income (expense):  
Interest income7,3202,038
Other expense, net(251)(55)
Total other income, net7,0691,983
Loss before equity method investment(66,460)(45,995)
Loss on equity method investment(470)0
Net loss$ (66,930)$ (45,995)
Net loss per share:  
Net loss per share - basic$ (0.93)$ (0.85)
Net loss per share - diluted$ (0.93)$ (0.85)
Weighted average shares - basic72,28953,908
Weighted average shares - diluted72,28953,908
Other comprehensive income (loss):  
Unrealized gain (loss) on investment securities$ (827)$ 1,417
Comprehensive loss$ (67,757)$ (44,578)

CRNX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 395,924$ 54,897
Investment securities505,037503,658
Prepaid expenses and other current assets16,26715,598
Total current assets917,228574,153
Property and equipment, net11,86510,881
Operating lease right-of-use assets45,76046,549
Investment in Radionetics0470
Restricted cash1,3001,300
Other assets2,0002,000
Total assets978,153635,353
Current liabilities:  
Accounts payable and accrued expenses28,68323,196
Accrued compensation and related expenses14,82914,517
Deferred revenue2,4632,056
Operating lease liabilities5,7924,173
Total current liabilities51,76743,942
Operating lease liabilities, non-current46,71247,555
Deferred revenue, non-current4,7414,750
Total liabilities103,22096,247
Commitments and contingencies (Note 7)
Stockholders’ equity:  
Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at March 31, 2024 or December 31, 202300
Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 78,539 shares issued and outstanding at March 31, 2024; 68,175 shares issued and outstanding at December 31, 20231,595,4151,191,831
Accumulated other comprehensive loss150977
Accumulated deficit(720,632)(653,702)
Total stockholders’ equity874,933539,106
Total liabilities and stockholders’ equity$ 978,153$ 635,353
CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.
 CEO
 WEBSITEcrinetics.com
 INDUSTRYBiotechnology
 EMPLOYEES210

Crinetics Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Crinetics Pharmaceuticals Inc? What does CRNX stand for in stocks?

CRNX is the stock ticker symbol of Crinetics Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Crinetics Pharmaceuticals Inc (CRNX)?

As of Thu Jun 13 2024, market cap of Crinetics Pharmaceuticals Inc is 3.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRNX stock?

You can check CRNX's fair value in chart for subscribers.

What is the fair value of CRNX stock?

You can check CRNX's fair value in chart for subscribers. The fair value of Crinetics Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Crinetics Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Crinetics Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CRNX is over valued or under valued. Whether Crinetics Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Crinetics Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRNX.

What is Crinetics Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, CRNX's PE ratio (Price to Earnings) is -15.69 and Price to Sales (PS) ratio is 1.87 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRNX PE ratio will change depending on the future growth rate expectations of investors.